Mydecine Innovations Group (STU:0NF0) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mydecine Innovations Group COGS-to-Revenue?

Mydecine Innovations Group's Cost of Goods Sold for the three months ended in Sep. 2023 was €0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was €0.00 Mil.

Mydecine Innovations Group's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Mydecine Innovations Group's Gross Margin % for the three months ended in Sep. 2023 was N/A%.

Mydecine Innovations Group COGS-to-Revenue Historical Data

The historical data trend for Mydecine Innovations Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group COGS-to-Revenue Chart

Mydecine Innovations Group Annual Data

Trend

Dec13

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

0.53

0.74

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Mydecine Innovations Group COGS-to-Revenue Calculation

Mydecine Innovations Group's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Mydecine Innovations Group's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Mydecine Innovations Group (STU:0NF0) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Mydecine Innovations Group's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Mydecine Innovations Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mydecine Innovations Group (STU:0NF0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (STU:0NF0) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

MYCOF:USA MYIG:UK MYCO:Canada

Address

789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group (STU:0NF0) Headlines

No Headlines